Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy

Am Heart J. 1999 May;137(5):S90-3. doi: 10.1016/s0002-8703(99)70438-2.
No abstract available

MeSH terms

  • Clinical Trials as Topic*
  • Cost-Benefit Analysis
  • Decision Making*
  • Fibrinolytic Agents / economics*
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Myocardial Infarction / drug therapy
  • North America
  • Retrospective Studies
  • Streptokinase / economics*
  • Streptokinase / therapeutic use
  • Thrombolytic Therapy / economics*
  • Tissue Plasminogen Activator / economics*
  • Tissue Plasminogen Activator / therapeutic use

Substances

  • Fibrinolytic Agents
  • Streptokinase
  • Tissue Plasminogen Activator